The wildly beating heart, fatigue and other debilitating symptoms are well known to the many millions of people impacted by atrial fibrillation. Some of those who have afib may have no outward symptoms, but are still at risk of serious and long-term damage to the heart. Symptoms or not, rate control is the common treatment …
Read More
Our January EP Lab Digest Patient Perspective column, Stuck in the Middle: Afib Patients on Rate Control, focuses on how rate control treatment (such as beta blockers) alone impacts the quality of life of those living with atrial fibrillation. The column also explores things doctors and patients may wish to consider in determining an appropriate …
Read More
In this video, Dr. Matthew Reynolds, of the Harvard Clinical Research Institute, discussed his quality of life findings from use of catheter ablation and antiarrhythmic drugs for treatment of atrial fibrillation. He analyzed quality of life data that was collected as part of the THERMOCOOL catheter trial in which catheter ablation was found to be …
Read More
The U.S. Food and Drug Administration (FDA) has approved the Medtronic Arctic Front® Cardiac CryoAblation Catheter system for the treatment of paroxysmal atrial fibrillation. This is the first cryo (freezing) catheter ablation system to receive approval in the US. Approval was based on the results of the STOP AF (Sustained Treatment of Paroxysmal Atrial Fibrillation) …
Read More
In this video, Dr. Douglas L. Packer of the Mayo Clinic provides details about the landmark CABANA Trial comparing Catheter Ablation to Antiarrhythmic Drugs for Atrial Fibrillation. Dr. Packer is the Lead Investigator for the CABANA Trial. Watch the video, and learn more, at: Dr. Douglas L. Packer on the CABANA Trial comparing Catheter Ablation to …
Read More